Ocumension Therapeutics is a pharmaceutical platform dedicated to identifying, developing, and commercializing ophthalmic therapies.
Business Model:
Revenue: $2M
Employees: 0-0
Address: Room 502-1, Wangwang Building, 211 Shimen 1st Road
City: Shanghai
State: shanghai municipality
Zip: 200000
Country: CN
Ocumension Therapeutics is a China-based ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first- or best-in-class ophthalmic therapies. The company’s vision is to provide a world-class pharmaceutical total solution to address significant unmet ophthalmic medical needs in China. Since the inception, Ocumension Therapeutics has focused on building a platform integrating specialized capabilities in each major functionality involved in an ophthalmic drug&s;s development cycle, from research and development, manufacturing to commercialization. Ocumension Therapeutics believes its platform positions it well to achieve leadership in China ophthalmology, with a first-mover advantage over future competitors.
Contact Phone:
Contact Email:
Listed Exchange:
HKG
IPO Date:
7/10/2020
Ticker Symbol:
1477
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
4/2021 | Alimera Sciences | Corporate Round | 20M |
1/2021 | EyePoint Pharmaceuticals | Post-IPO Equity | 0 |
4/2021 | Alimera Sciences | Post-IPO Equity | 0 |
1/2021 | EyePoint Pharmaceuticals | Post-IPO Equity | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|